Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 143 (5) , 4A-10A
- https://doi.org/10.1067/mhj.2002.121806
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Primary Pulmonary HypertensionCirculation, 2000
- Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibitionActa Crystallographica Section C Crystal Structure Communications, 2000
- Prostacyclin Synthase Expression Is Decreased in Lungs from Patients with Severe Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Guanidine Derivatives as Combined Thromboxane A2 Receptor Antagonists and Synthase InhibitorsJournal of Medicinal Chemistry, 1999
- Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.Journal of Clinical Investigation, 1998
- Effects of terbogrel on platelet function and prostaglandin endoperoxide transferEuropean Journal of Pharmacology, 1998
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992
- Thromboxane Synthetase Inhibition in Primary Pulmonary HypertensionChest, 1987